Register Login

Global Diversity in VTE Research

Check your local medical library for: Lim HY, Scheres LJJ, Okoye H, Chen Q, Fan BE, Ajjan R, Favaloro EJ, Ho P. Global Diversity in Venous Thromboembolism Care and Research: An Equity and Scientific Imperative. Semin Thromb Hemost. 2026 Nov 20. doi: 10.1055/a-2997-0503. PMID: 43063980. You can also request a reprint from author Hui Y. Lim.

Abstract

Venous thromboembolism (VTE) affects millions of people worldwide and remains a major cause of morbidity and mortality across low-, middle-, and high-income countries.[1] Yet the evidence underpinning VTE epidemiology, diagnosis, risk prediction, and therapy has been generated overwhelmingly in populations of European ancestry.[2] Consequently, current understanding of VTE biology, diagnostic pathways, and clinical outcomes may not fully reflect the diverse populations encountered in global clinical practice.

It is useful to distinguish three complementary dimensions of diversity in biomedical research. The first is representation and equity: who is enrolled in clinical studies, and are these findings distributed fairly? The second is social and environmental diversity: how do health care access, socioeconomic conditions, health care systems, and environmental exposures influence disease and outcomes?[3] [4] The third, ancestral diversity, is biological: the genetic, molecular, and cellular variations across human populations that shape disease mechanisms and treatment response.[5] Although all three dimensions remain incompletely addressed, particularly in resource-limited settings, ancestral diversity has received comparatively less attention in VTE research. This matters because ancestral diversity is not merely a question of fairness. In complex disease genetics, ancestrally diverse cohorts have become a powerful engine of discovery, improving variant identification and the performance of predictive models.[5] In VTE, these advances could reveal previously unrecognized thrombosis risk factors, refine risk prediction, and enable more precise tailoring of thromboprophylaxis and anticoagulant therapy, bringing the field closer to precision thrombosis medicine.

We, therefore, propose that ancestral diversity be recognized as a foundational scientific principle in VTE research, not as a confounder or recruitment quota, but as a source of biological insight. First, ancestry should be viewed as a continuum rather than a set of discrete population labels, which are shaped by social, historical, and migration context, and distinguished from socially constructed racial categories.[5] Second, the objective is not to attribute biology to broad ethnic groups, but to use ancestrally diverse populations to identify the mechanisms underlying disease heterogeneity and therapeutic outcomes. This is particularly important for African populations, which encompass substantial genetic diversity and should not be treated as a single homogeneous group.[6] Meaningful representation of African ancestry, therefore, requires inclusion of diverse populations across the continent rather than relying on a single African population as a proxy for Africa as a whole.

Comments (0)
Thrombophilia

No comments here.

Leave a Reply